Clinical Trial Update: Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety and effectiveness of propagermanium in patients with focal segmental glomerulosclerosis receiving irbesartan has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• Irbesartan (irbesartan)
• Propagermanium (propagermanium)

Snippet

Sponsor: Dimerix Bioscience Pty Ltd | Conditions: Focal Segmental Glomerulosclerosis | Phase 2 | Status: COMPLETED